{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:01:30Z","timestamp":1785492090492,"version":"3.56.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12498-z","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:54:34Z","timestamp":1785491674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Variant-specific contributions of CYP21A2 and CYP11B1 to the clinical and hormonal heterogeneity of polyendocrine metabolic ovarian syndrome phenotypes"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1209-9602","authenticated-orcid":false,"given":"Seher","family":"Polat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasin","family":"Simsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"10545","key":"12498_CR1","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/S0140-6736(26)00717-8","volume":"407","author":"HJ Teede","year":"2026","unstructured":"Teede HJ, Khomami MB, Morman R, Laven JSE, Joham AE, Costello MF, Patil M, Rees DA, Berry L, Cree MG, Zhao H, Norman RJ, Dokras A, Piltonen T, Global Name Change Consortium (2026) Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet 407(10545):2329\u20132339. https:\/\/doi.org\/10.1016\/S0140-6736(26)00717-8","journal-title":"Lancet"},{"issue":"3","key":"12498_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/humupd\/dmaf030","volume":"32","author":"ACH Neven","year":"2026","unstructured":"Neven ACH, Forslund M, Ranasinha S, Sethi P, Dhungana RR, Mousa A, Tay CT, Teede H, Boyle JA (2026) Prevalence of polycystic ovary syndrome: a global and regional systematic review and meta-analysis. Hum Reprod Update 32(3):277\u2013312. https:\/\/doi.org\/10.1093\/humupd\/dmaf030","journal-title":"Hum Reprod Update"},{"issue":"4","key":"12498_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/humrep\/det469","volume":"29","author":"MP Lauritsen","year":"2014","unstructured":"Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, Cohen A, Hougaard DM, Nyboe Andersen A (2014) The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod 29(4):791\u2013801. https:\/\/doi.org\/10.1093\/humrep\/det469","journal-title":"Hum Reprod"},{"issue":"2","key":"12498_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1210\/jc.2003-031122","volume":"89","author":"R Azziz","year":"2004","unstructured":"Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR (2004) Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 89(2):453\u2013462. https:\/\/doi.org\/10.1210\/jc.2003-031122","journal-title":"J Clin Endocrinol Metab"},{"key":"12498_CR5","doi-asserted-by":"publisher","first-page":"100937","DOI":"10.1016\/j.molmet.2020.01.001","volume":"35","author":"MA Sanchez-Garrido","year":"2020","unstructured":"Sanchez-Garrido MA, Tena-Sempere M (2020) Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab 35:100937. https:\/\/doi.org\/10.1016\/j.molmet.2020.01.001","journal-title":"Mol Metab"},{"issue":"12","key":"12498_CR6","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1210\/jc.2017-01415","volume":"102","author":"S Brakta","year":"2017","unstructured":"Brakta S, Lizneva D, Mykhalchenko K, Imam A, Walker W, Diamond MP, Azziz R (2017) Perspectives on Polycystic Ovary Syndrome: Is Polycystic Ovary Syndrome Research Underfunded? J Clin Endocrinol Metabolism 102(12):4421\u20134427. https:\/\/doi.org\/10.1210\/jc.2017-01415","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"3","key":"12498_CR7","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/humrep\/17.3.620","volume":"17","author":"T Piltonen","year":"2002","unstructured":"Piltonen T, Koivunen R, Morin-Papunen L, Ruokonen A, Huhtaniemi IT, Tapanainen JS (2002) Ovarian and adrenal steroid production: regulatory role of LH\/HCG. Hum Reprod 17(3):620\u2013624. https:\/\/doi.org\/10.1093\/humrep\/17.3.620","journal-title":"Hum Reprod"},{"issue":"10","key":"12498_CR8","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1210\/jc.86.10.5060","volume":"86","author":"B Couzinet","year":"2001","unstructured":"Couzinet B, Meduri G, Lecce MG, Young J, Brailly S, Loosfelt H, Milgrom E, Schaison G (2001) The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metabolism 86(10):5060\u20135066. https:\/\/doi.org\/10.1210\/jc.86.10.5060","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"Suppl 5","key":"12498_CR9","first-page":"1315","volume":"13","author":"SF Witchel","year":"2000","unstructured":"Witchel SF, Aston CE (2000) The role of heterozygosity for CYP21 in the polycystic ovary syndrome. J Pediatr Endocrinol Metab 13(Suppl 5):1315\u20131317","journal-title":"J Pediatr Endocrinol Metab"},{"key":"12498_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1196\/annals.1365.011","volume":"1092","author":"E Carmina","year":"2006","unstructured":"Carmina E (2006) Ovarian and adrenal hyperandrogenism. Ann N Y Acad Sci 1092:130\u2013137. https:\/\/doi.org\/10.1196\/annals.1365.011","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"12498_CR11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/humupd\/dmx014","volume":"23","author":"E Carmina","year":"2017","unstructured":"Carmina E, Dewailly D, Escobar-Morreale HF, Kelestimur F, Moran C, Oberfield S, Witchel SF, Azziz R (2017) Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum Reprod Update 23(5):580\u2013599. https:\/\/doi.org\/10.1093\/humupd\/dmx014","journal-title":"Hum Reprod Update"},{"issue":"5","key":"12498_CR12","doi-asserted-by":"publisher","first-page":"e250126","DOI":"10.1530\/REP-25-0126","volume":"170","author":"YV Louwers","year":"2025","unstructured":"Louwers YV, Visser JA, Dunaif A, Laven JSE (2025) Polycystic ovary syndrome origins and implications: genetics of polycystic ovary syndrome (PCOS). Reproduction 170(5):e250126. https:\/\/doi.org\/10.1530\/REP-25-0126","journal-title":"Reproduction"},{"key":"12498_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/Tacg.S200341","volume":"12","author":"MJ Khan","year":"2019","unstructured":"Khan MJ, Ullah A, Basit S (2019) Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives. Application Clin Genet 12:249\u2013260. https:\/\/doi.org\/10.2147\/Tacg.S200341","journal-title":"Application Clin Genet"},{"key":"12498_CR14","doi-asserted-by":"crossref","unstructured":"Ghanegolmohammadi F, Ohnuki S, Byrne S, Raman R, Begley TJ, Dedon PC (2026) Synonymous codon usage defines functional gene families. BMC Biol 24(1). https:\/\/doi.org\/ARTN","DOI":"10.1186\/s12915-026-02505-x"},{"issue":"7","key":"12498_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S2213-8587(25)00405-X","volume":"14","author":"A Huerta-Chagoya","year":"2026","unstructured":"Huerta-Chagoya A, Kim J, Mandla R, Lu Y, Suzuki K, Petty LE, Ng HK, Choi J, Lee S, Rout M, Lin K, Taylor K, ENSA Genomics Consortium; Genes & Health Research Team; VA Million Veteran Program, Aguilar-Salinas CA, Garc\u00eda-Garc\u00eda L, Gonz\u00e1lez-Villalpando C, Haiman CA, Kim YJ, Kwak SH, Leong A, Loos RJF, Moreno-Estrada A, Morris AP, Orozco L, Rotter JI, Sanghera D, Tusie-Luna T, Voight BF, Vujkovic M, Walters RG, Ge T, Manning AK, Loh M, Below JE, Sim X, Mercader JM, Ng MCY, D-PRISM Consortium (2026) Multi-ancestry polygenic risk scores for the prediction of type 2 diabetes and complications in diverse ancestries. Lancet Diabetes Endocrinol 14(7):558\u2013569. https:\/\/doi.org\/10.1016\/S2213-8587(25)00405-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"12498_CR16","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1210\/jc.2006-0178","volume":"91","author":"R Azziz","year":"2006","unstructured":"Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF (2006) Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91(11):4237\u20134245. https:\/\/doi.org\/10.1210\/jc.2006-0178","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"12498_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/humupd\/dmp024","volume":"16","author":"BO Yildiz","year":"2010","unstructured":"Yildiz BO, Bolour S, Woods K, Moore A, Azziz R (2010) Visually scoring hirsutism. Hum Reprod Update 16(1):51\u201364. https:\/\/doi.org\/10.1093\/humupd\/dmp024","journal-title":"Hum Reprod Update"},{"issue":"4","key":"12498_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.fertnstert.2023.07.025","volume":"120","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, L MR, J AB and others (2023) Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril 120(4):767\u2013793. https:\/\/doi.org\/10.1016\/j.fertnstert.2023.07.025","journal-title":"Fertil Steril"},{"issue":"1","key":"12498_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2337\/diacare.23.1.57","volume":"23","author":"E Bonora","year":"2000","unstructured":"Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23(1):57\u201363","journal-title":"Diabetes Care"},{"issue":"6","key":"12498_CR20","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1210\/jcem.77.6.7903314","volume":"77","author":"Y Naiki","year":"1993","unstructured":"Naiki Y, Kawamoto T, Mitsuuchi Y, Miyahara K, Toda K, Orii T, Imura H, Shizuta Y (1993) A nonsense mutation (TGG [Trp116]TAG [Stop]) in CYP11B1 causes steroid 11 beta-hydroxylase deficiency. J Clin Endocrinol Metab 77(6):1677\u20131682. https:\/\/doi.org\/10.1210\/jcem.77.6.7903314","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"12498_CR21","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1210\/jcem.78.5.8175971","volume":"78","author":"A Wedell","year":"1994","unstructured":"Wedell A, Thilen A, Ritzen EM, Stengler B, Luthman H (1994) Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 78(5):1145\u20131152. https:\/\/doi.org\/10.1210\/jcem.78.5.8175971","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"12498_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1203\/00006450-199311000-00026","volume":"34","author":"YT Chang","year":"1993","unstructured":"Chang YT, Kappy MS, Iwamoto K, Wang J, Yang X, Pang S (1993) Mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene in a patient with classic salt-wasting 3 beta-hydroxysteroid dehydrogenase deficiency congenital adrenal hyperplasia. Pediatr Res 34(5):698\u2013700. https:\/\/doi.org\/10.1203\/00006450-199311000-00026","journal-title":"Pediatr Res"},{"issue":"10","key":"12498_CR23","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1210\/jc.2006-2163","volume":"92","author":"RS Araujo","year":"2007","unstructured":"Araujo RS, Mendonca BB, Barbosa AS, Lin CJ, Marcondes JA, Billerbeck AE, Bachega TA (2007) Microconversion between CYP21A2 and CYP21A1P promoter regions causes the nonclassical form of 21-hydroxylase deficiency. J Clin Endocrinol Metab 92(10):4028\u20134034. https:\/\/doi.org\/10.1210\/jc.2006-2163","journal-title":"J Clin Endocrinol Metab"},{"key":"12498_CR24","doi-asserted-by":"crossref","unstructured":"Fanis P, Skordis N, Toumba M, Picolos M, Tanteles GA, Neocleous V, Phylactou LA (2023) The pathogenic p.Gln319Ter variant is not causing congenital adrenal hyperplasia when inherited in one of the duplicated CYP21A2 genes. Front Endocrinol 14. https:\/\/doi.org\/ARTN","DOI":"10.3389\/fendo.2023.1156616"},{"issue":"1","key":"12498_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4274\/jcrpe.galenos.2021.2021.0184","volume":"14","author":"S Polat","year":"2022","unstructured":"Polat S, Arslan YK (2022) 17-Hydroxyprogesterone Response to Standard Dose Synacthen Stimulation Test in CYP21A2 Heterozygous Carriers and Non-carriers in Symptomatic and Asymptomatic Groups: Meta-analyses. J Clin Res Pediatr Endocrinol 14(1):56\u201368. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2021.2021.0184","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"12498_CR26","doi-asserted-by":"publisher","unstructured":"Qu X, Donnelly R (2020) Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome. Int J Mol Sci 21(21). https:\/\/doi.org\/10.3390\/ijms21218191","DOI":"10.3390\/ijms21218191"},{"key":"12498_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/IJWH.S344542","volume":"14","author":"C Xing","year":"2022","unstructured":"Xing C, Zhang J, Zhao H, He B (2022) Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment. Int J Womens Health 14:91\u2013105. https:\/\/doi.org\/10.2147\/IJWH.S344542","journal-title":"Int J Womens Health"},{"issue":"1","key":"12498_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1210\/er.2010-0013","volume":"32","author":"WL Miller","year":"2011","unstructured":"Miller WL, Auchus RJ (2011) The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 32(1):81\u2013151. https:\/\/doi.org\/10.1210\/er.2010-0013","journal-title":"Endocr Rev"},{"issue":"3","key":"12498_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1210\/edrv.21.3.0398","volume":"21","author":"PC White","year":"2000","unstructured":"White PC, Speiser PW (2000) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 21(3):245\u2013291. https:\/\/doi.org\/10.1210\/edrv.21.3.0398","journal-title":"Endocr Rev"},{"key":"12498_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cca.2016.11.037","volume":"464","author":"R Khajuria","year":"2017","unstructured":"Khajuria R, Walia R, Bhansali A, Prasad R (2017) The spectrum of CYP21A2 mutations in Congenital Adrenal Hyperplasia in an Indian cohort. Clin Chim Acta 464:189\u2013194. https:\/\/doi.org\/10.1016\/j.cca.2016.11.037","journal-title":"Clin Chim Acta"},{"issue":"Suppl 1","key":"12498_CR31","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.4103\/2230-8210.145077","volume":"18","author":"V Neocleous","year":"2014","unstructured":"Neocleous V, Shammas C, Phedonos AA, Phylactou LA, Skordis N (2014) Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations. Indian J Endocrinol Metab 18(Suppl 1):S72\u2013S79. https:\/\/doi.org\/10.4103\/2230-8210.145077","journal-title":"Indian J Endocrinol Metab"},{"key":"12498_CR32","doi-asserted-by":"crossref","unstructured":"Ordonez-Sanchez ML, Ramirez-Jimenez S, Lopez-Gutierrez AU, Riba L, Gamboa-Cardiel S, Cerrillo-Hinojosa M, Altamirano-Bustamante N, Calzada-Leon R, Robles-Valdes C, Mendoza-Morfin F (1998) and others Molecular genetic analysis of patients carrying steroid 21-hydroxylase deficiency in the Mexican population: identification of possible new mutations and high prevalence of apparent germ-line mutations. Human genetics 102(2):170-7","DOI":"10.1007\/s004390050672"},{"issue":"5","key":"12498_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s100380050167","volume":"44","author":"A Asanuma","year":"1999","unstructured":"Asanuma A, Ohura T, Ogawa E, Sato S, Igarashi Y, Matsubara Y, Iinuma K (1999) Molecular analysis of Japanese patients with steroid 21-hydroxylase deficiency. J Hum Genet 44(5):312\u2013317. https:\/\/doi.org\/10.1007\/s100380050167","journal-title":"J Hum Genet"},{"issue":"3","key":"12498_CR34","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4103\/jhrs.jhrs_86_22","volume":"15","author":"P Sharma","year":"2022","unstructured":"Sharma P, Jain M, Halder A (2022) An investigation of steroid biosynthesis pathway genes in women with polycystic ovary syndrome. J Hum Reproductive Sci 15(3):240\u2013249. https:\/\/doi.org\/10.4103\/jhrs.jhrs_86_22","journal-title":"J Hum Reproductive Sci"},{"issue":"2","key":"12498_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40200-018-0371-5","volume":"17","author":"S Toosy","year":"2018","unstructured":"Toosy S, Sodi R, Pappachan JM (2018) Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. J Diabetes Metab Disord 17(2):277\u2013285. https:\/\/doi.org\/10.1007\/s40200-018-0371-5","journal-title":"J Diabetes Metab Disord"},{"key":"12498_CR36","doi-asserted-by":"publisher","unstructured":"Doleschall M, Szabo JA, Pazmandi J, Szilagyi A, Koncz K, Farkas H, Toth M, Igaz P, Glaz E, Prohaszka Z (2014) and others Common genetic variants of the human steroid 21-hydroxylase gene (CYP21A2) are related to differences in circulating hormone levels. PLoS One 9(9):e107244. https:\/\/doi.org\/10.1371\/journal.pone.0107244","DOI":"10.1371\/journal.pone.0107244"},{"issue":"2","key":"12498_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1530\/EC-14-0032","volume":"3","author":"I Bronstad","year":"2014","unstructured":"Bronstad I, Breivik L, Methlie P, Wolff AS, Bratland E, Nermoen I, Lovas K, Husebye ES (2014) Functional studies of novel CYP21A2 mutations detected in Norwegian patients with congenital adrenal hyperplasia. Endocr connections 3(2):67\u201374. https:\/\/doi.org\/10.1530\/EC-14-0032","journal-title":"Endocr connections"},{"issue":"1","key":"12498_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/cen.12526","volume":"82","author":"M Barbaro","year":"2015","unstructured":"Barbaro M, Soardi FC, Ostberg LJ, Persson B, de Mello MP, Wedell A, Lajic S (2015) In vitro functional studies of rare CYP21A2 mutations and establishment of an activity gradient for nonclassic mutations improve phenotype predictions in congenital adrenal hyperplasia. Clin Endocrinol 82(1):37\u201344. https:\/\/doi.org\/10.1111\/cen.12526","journal-title":"Clin Endocrinol"},{"issue":"1","key":"12498_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2899","volume":"12","author":"JB Plotkin","year":"2011","unstructured":"Plotkin JB, Kudla G (2011) Synonymous but not the same: the causes and consequences of codon bias. Nat Rev Genet 12(1):32\u201342. https:\/\/doi.org\/10.1038\/nrg2899","journal-title":"Nat Rev Genet"},{"key":"12498_CR40","doi-asserted-by":"crossref","unstructured":"G\u00fcm\u00fcsg\u00fcl MD, Sahin S, Turan HK, Karaca BT, Yenenler-Kutlu A (2020) Elucidating the roles of naturally occurring silent mutations in Polycystic Ovary Syndrome (PCOS). Meta Gene 25. https:\/\/doi.org\/ARTN10070710.1016\/j.mgene.2020.100707","DOI":"10.1016\/j.mgene.2020.100707"},{"issue":"1","key":"12498_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cub.2012.11.031","volume":"23","author":"BL Lampson","year":"2013","unstructured":"Lampson BL, Pershing NL, Prinz JA, Lacsina JR, Marzluff WF, Nicchitta CV, MacAlpine DM, Counter CM (2013) Rare codons regulate KRas oncogenesis. Curr biology: CB 23(1):70\u201375. https:\/\/doi.org\/10.1016\/j.cub.2012.11.031","journal-title":"Curr biology: CB"},{"issue":"35","key":"12498_CR42","doi-asserted-by":"publisher","first-page":"20961","DOI":"10.1016\/S0021-9258(19)30030-4","volume":"264","author":"E Mornet","year":"1989","unstructured":"Mornet E, Dupont J, Vitek A, White PC (1989) Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem 264(35):20961\u201320967","journal-title":"J Biol Chem"},{"key":"12498_CR43","doi-asserted-by":"publisher","unstructured":"Lisurek M, Bernhardt R (2004) Modulation of aldosterone and cortisol synthesis on the molecular level. Mol Cell Endocrinol 215(1\u20132):149\u201359. https:\/\/doi.org\/10.1016\/j.mce.2003.11.008","DOI":"10.1016\/j.mce.2003.11.008"},{"key":"12498_CR44","unstructured":"Barr M (2006) A study of genetic variability at the CYP11B2\/B1 locus and its importance in human hypertension [PhD Thesis]. : UNIVERSITY of GLASGOW; 2006. 1-296 p"},{"key":"12498_CR45","doi-asserted-by":"publisher","unstructured":"Parajes S, Loidi L, Reisch N, Dhir V, Rose IT, Hampel R, Quinkler M, Conway GS, Castro-Feijoo L, Araujo-Vilar D (2010) and others Functional consequences of seven novel mutations in the CYP11B1 gene: four mutations associated with nonclassic and three mutations causing classic 11{beta}-hydroxylase deficiency. The Journal of clinical endocrinology and metabolism 95(2):779\u2009\u2013\u200988. https:\/\/doi.org\/10.1210\/jc.2009-0651","DOI":"10.1210\/jc.2009-0651"},{"issue":"1","key":"12498_CR46","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1210\/jcem.83.1.4513","volume":"83","author":"DP Merke","year":"1998","unstructured":"Merke DP, Tajima T, Chhabra A, Barnes K, Mancilla E, Baron J, Cutler GB Jr. (1998) Novel CYP11B1 mutations in congenital adrenal hyperplasia due to steroid 11 beta-hydroxylase deficiency. J Clin Endocrinol Metab 83(1):270\u2013273. https:\/\/doi.org\/10.1210\/jcem.83.1.4513","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"12498_CR47","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1073\/pnas.89.11.4996","volume":"89","author":"L Pascoe","year":"1992","unstructured":"Pascoe L, Curnow KM, Slutsker L, Rosler A, White PC (1992) Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci USA 89(11):4996\u20135000","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12498-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:54:35Z","timestamp":1785491675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12498-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12498"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12498-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflicts of interest relevant to the subject matter or materials included in this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Medical School at Erzincan University with approval number 33216249-604.01.02-E.3294. All procedures performed in studies involving human participants and\/or animals were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1313"}}